Wu, Xiaoliang
Ma, Wenjuan
Zhou, Qianghua
Yan, Haijuan
Lim, Zuan-Fu
Huang, Mayan
Deng, Chuangzhong
Yu, Xingsu
Su, Huifang
Komo, Satoshi
Yang, Haixia
Zhang, Xinke
Wen, Sijin
Zhang, Zhenfeng
Ma, Patrick C.
Funding for this research was provided by:
National Natural Science Foundation of China (81372274, 81461168028)
National Natural Science Foundation of China (81672276)
Natural Science Foundation of Guangdong Province (2014A030313033, 2014A050503037)
National Institute of General Medical Sciences (U54GM104942)
Guizhou Provincial People’s Hospital Youth Funding (GZSQN [2016]20)
Article History
Received: 5 February 2017
Accepted: 24 March 2017
First Online: 27 May 2017
Compliance with ethical standards
:
: Patrick C. Ma is a member of Speaker’s Bureau of Merck and Pfizer, Advisory Board of Caris Center of Excellence Network for Precision Medicine (Caris Life Science) and received contracted clinical research support from Medimmune, Bristol-Myers Squibb, AstraZeneca, EpicentRx, Tesaro, PrECOG, LOXO Oncology, and XCovery.
: This study was approved by Sun Yat-sen University Cancer Center Institutional Review Board (IRB) and Human Ethics Committee (HEC).
: Informed consent was obtained from all individual participants included in the study.